The results of the CheckMate 057 study have recently shown that PD-L1 expression (cut-off point 1%) significantly correlated with ORR (overall response rates), PFS (progression free survival) and OS, in pre-treated NSCLC patients [32]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.